Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-10 |
2024-03 |
-0.23 |
-0.29 |
-0.06 |
-26.09% |
2024-03-22 |
2023-12 |
-0.25 |
N/A |
N/A |
N/A |
2024-03-22 |
2023-12 |
-0.25 |
-0.24 |
0.01 |
4.00% |
2023-11-09 |
2023-09 |
-0.25 |
-0.25 |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.25 |
N/A |
N/A |
N/A |
2023-08-14 |
2023-06 |
-0.22 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-20 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-30 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-23 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-14 |
Benchmark |
Upgrade |
Buy |
Buy |
2023-06-21 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2023-06-11 |
Benchmark |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-08-20 |
AYABUDGE, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
8.19M |
Sale |
2024-05-14 |
BINDER GORDON M |
Director |
0.00 |
Purchase |
2023-05-17 |
CONSTANTINO MICHAEL T |
Director |
9.25K |
Purchase |
2023-10-09 |
DOUGAN BRADY W |
Director |
0.00 |
Conversion of Exercise of derivative security |
2021-08-25 |
LAWSON JEFFREY HAROLD |
Officer and Director |
7.88K |
Stock Award(Grant) |
2023-10-09 |
NIKLASON LAURA E |
Chief Executive Officer |
8.09M |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
4.30M |
12.31M |
4.16% |
2023-06-29 |
Vanguard Group Inc |
2.97M |
8.49M |
2.87% |
2023-06-29 |
Geode Capital Management, LLC |
1.10M |
3.15M |
1.07% |
2023-06-29 |
State Street Corporation |
1.04M |
2.97M |
1.00% |
2023-06-29 |
Prescott General Partners LLC |
568.25K |
1.63M |
0.55% |
2023-06-29 |
Northern Trust Corporation |
500.01K |
1.43M |
0.48% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.62M |
4.64M |
1.57% |
2023-08-30 |
iShares Russell 2000 ETF |
1.41M |
5.42M |
1.37% |
2023-06-29 |
Vanguard Extended Market Index Fund |
757.72K |
2.17M |
0.73% |
2023-07-30 |
Fidelity Small Cap Index Fund |
539.20K |
1.77M |
0.52% |
2023-08-30 |
iShares Russell 2000 Growth ETF |
453.04K |
1.74M |
0.44% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
395.59K |
1.52M |
0.38% |